SLU-PP-332 is a small-molecule agonist of the estrogen-related receptors, favoring ERRalpha, and not a peptide. Labs describe it as an exercise mimetic that boosts mitochondrial function, fat oxidation, and endurance, but the data comes entirely from cell and rodent studies with no human trials as of 2026. It is not FDA-approved and sells only for laboratory use. Below you'll find reported dosing plus safety and legal notes. Educational only, not medical advice.
A small-molecule synthetic agonist of the estrogen-related receptors (preferential for ERRalpha) -- NOT a peptide. It is described as an 'exercise mimetic' that induces an ERRalpha-dependent gene program increasing mitochondrial function, fatty-acid oxidation, and endurance.
Half-life
Short in preclinical models (reported on the order of a couple of hours in mice); human pharmacokinetics are unknown. It is a small molecule, not a peptide.
Regulatory status
Not FDA-approved. No registered or completed human clinical trials as of 2026. Sold as a research chemical / for laboratory use only.
Safety
No human safety data whatsoever; all risk information is theoretical or from animal models. Human-use claims are unsupported.
Evidence
Preclinical only -- cell and rodent studies (e.g., endurance and metabolic models).
Sources
Billon C, Sitaula S, Banerjee S, et al. Synthetic ERR alpha/beta/gamma Agonist Induces an ERR alpha-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS Chem Biol. 2023;18(4):756-771. https://pubmed.ncbi.nlm.nih.gov/36988910/
Billon C, Schoepke E, Avdagic A, et al. A Synthetic ERR Agonist Alleviates Metabolic Syndrome. J Pharmacol Exp Ther. 2024;388(2):232-240. https://pubmed.ncbi.nlm.nih.gov/37739806/
Wang XX, Myakala K, Libby AE, et al. Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney. Am J Pathol. 2023;193(12):1969-1987. https://pubmed.ncbi.nlm.nih.gov/37717940/
Xu W, Billon C, Li H, et al. Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function. Circulation. 2024;149(3):227-250. https://pubmed.ncbi.nlm.nih.gov/37961903/
Avliyakulov NK, Sobolevsky T, Ahrens E. In Vitro Metabolites of SLU-PP-332 for Doping-Control Purposes. Drug Test Anal. 2026;18(3):439-450. https://pubmed.ncbi.nlm.nih.gov/41688415/
Stein RA, Chang CY, Kazmin DA, et al. Estrogen-related receptor alpha is critical for the growth of ER-negative breast cancer. Cancer Res. 2008;68(21):8805-8812. https://pubmed.ncbi.nlm.nih.gov/18974123/
Muduli K, Prusty M, Pradhan J, et al. ERR alpha Promotes Cancer Stem Cell-Like Characteristics in Breast Cancer. Stem Cell Rev Rep. 2023;19(8):2807-2819. https://pubmed.ncbi.nlm.nih.gov/37584854/
PepWise is an informational and educational tracking tool, not medical advice and not a medical device. SLU-PP-332 may be experimental, restricted, or prescription-only; many research peptides are not FDA-approved. Consult a licensed healthcare provider before starting, changing, or stopping any protocol. Operated by STC Consulting, Inc.
